Differences in gene expression for several commonly encountered immune antigens, such as CD3, CD4, CD8, and CTLA4, were not statistically significant, likely reflecting the long length of time (average 323 days) between the last IPI dose and post-treatment biopsies. Although our sample size is ...
Methods ScRNAseq profiling of peripheral blood mononuclear cells (PBMCs) was performed on a subset of CheckMate-069 clinical trial (NCT01927419) samples, which included 52 patients with metastatic melanoma treated with either IPI (n=26) or NIVO + IPI (n=26), using the 5 prime 10x Genomics ...
Regional Lymph Node Basin (RLNB) Relapse after Adjuvant Ipilimumab (Ipi) Anti-CTLA4 Immunotherapy in Stage III Melanoma: A Subgroup Analysis of a Randomized Placebo-Controlled TrialThere has been much recent attention on immunotherapy for cancer due to the promising results of several randomized ...